{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:35:12Z","timestamp":1791668112271,"version":"4.3.4"},"reference-count":151,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"vor","delay-in-days":731,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cysticfibrosisjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.jcf.2015.03.003","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T20:50:12Z","timestamp":1428958212000},"page":"419-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":471,"title":["Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy"],"prefix":"10.1016","volume":"14","author":[{"given":"Andr\u00e9 M.","family":"Cantin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Chmiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2015.03.003_bb0005","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1164\/rccm.201004-0643OC","article-title":"Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children","volume":"182","author":"Meyerholz","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"29","key":"10.1016\/j.jcf.2015.03.003_bb0010","doi-asserted-by":"crossref","first-page":"ra31","DOI":"10.1126\/scitranslmed.3000928","article-title":"Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth","volume":"2","author":"Stoltz","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1164\/ajrccm.160.1.9808096","article-title":"Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients","volume":"160","author":"Muhlebach","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0020","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.201206-1150OC","article-title":"A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection","volume":"187","author":"Tiringer","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0030","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/BF02087437","article-title":"Crohn's disease and cystic fibrosis","volume":"39","author":"Lloyd-Still","year":"1994","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jcf.2015.03.003_bb0035","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA [published erratum appears in Science 1989 Sep 29;245(4925):1437]","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jcf.2015.03.003_bb0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11130","article-title":"Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung","volume":"487","author":"Pezzulo","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2015.03.003_bb0045","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1255825","article-title":"Cystic fibrosis impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis","volume":"345","author":"Hoegger","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jcf.2015.03.003_bb0050","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0169-409X(02)00144-8","article-title":"An overview of the pathogenesis of cystic fibrosis lung disease","volume":"54","author":"Boucher","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jcf.2015.03.003_bb0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev.med.58.071905.105316","article-title":"Airway surface dehydration in cystic fibrosis: pathogenesis and therapy","volume":"58","author":"Boucher","year":"2007","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0060","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.freeradbiomed.2004.07.027","article-title":"Reevaluating gel-forming mucins' roles in cystic fibrosis lung disease","volume":"37","author":"Perez-Vilar","year":"2004","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0065","first-page":"02014","article-title":"CFTR and lung homeostasis","volume":"00326","author":"Collawn","year":"2014","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0070","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1126\/science.1223012","article-title":"A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia","volume":"337","author":"Button","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jcf.2015.03.003_bb0075","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200508-1330OC","article-title":"Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers","volume":"173","author":"Cantin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0080","doi-asserted-by":"crossref","first-page":"C862","DOI":"10.1152\/ajpcell.00108.2005","article-title":"Pseudomonas aeruginosa inhibits endocytic recycling of CFTR in polarized human airway epithelial cells","volume":"290","author":"Swiatecka-Urban","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0085","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI0213870","article-title":"Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients","volume":"109","author":"Worlitzsch","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0090","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood-2007-10-115758","article-title":"HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling","volume":"111","author":"Scortegagna","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcf.2015.03.003_bb0095","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jcf.2011.02.005","article-title":"Impaired expression of hypoxia-inducible factor-1alpha in cystic fibrosis airway epithelial cells \u2014 a role for HIF-1 in the pathophysiology of CF?","volume":"10","author":"Legendre","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2015.03.003_bb0100","doi-asserted-by":"crossref","first-page":"C741","DOI":"10.1152\/ajpcell.00379.2005","article-title":"Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis","volume":"290","author":"Song","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0105","first-page":"291","article-title":"cAMP stimulation of HCO3-secretion across airway epithelia","volume":"2","author":"Welsh","year":"2001","journal-title":"JOP"},{"key":"10.1016\/j.jcf.2015.03.003_bb0110","doi-asserted-by":"crossref","first-page":"16083","DOI":"10.1073\/pnas.2634339100","article-title":"Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium","volume":"100","author":"Coakley","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2015.03.003_bb0115","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1165\/rcmb.2013-0418OC","article-title":"Native small airways secrete bicarbonate","volume":"50","author":"Shamsuddin","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0120","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1073\/pnas.91.12.5340","article-title":"Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator","volume":"91","author":"Poulsen","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2015.03.003_bb0125","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1172\/JCI40598","article-title":"Pass the bicarb: the importance of HCO3\u2212for mucin release","volume":"119","author":"De Lisle","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0130","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1172\/JCI38662","article-title":"Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion","volume":"119","author":"Garcia","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0135","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1084\/jem.20120562","article-title":"Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype","volume":"209","author":"Gustafsson","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0140","first-page":"39","article-title":"The role of sphingolipids and ceramide in pulmonary inflammation in cystic fibrosis","volume":"4","author":"Becker","year":"2010","journal-title":"Open Respir Med J"},{"key":"10.1016\/j.jcf.2015.03.003_bb0145","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nm823","article-title":"Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts","volume":"9","author":"Grassme","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0150","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1159\/000350071","article-title":"Therapy of CF-patients with amitriptyline and placebo\u2014a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study","volume":"31","author":"Nahrlich","year":"2013","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jcf.2015.03.003_bb0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1165\/rcmb.2008-0279OC","article-title":"Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide","volume":"41","author":"Guilbault","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1165\/rcmb.2007-0036OC","article-title":"Fenretinide corrects newly found ceramide deficiency in cystic fibrosis","volume":"38","author":"Guilbault","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0165","doi-asserted-by":"crossref","first-page":"674968","DOI":"10.1155\/2011\/674968","article-title":"Ceramide in cystic fibrosis: a potential new target for therapeutic intervention","volume":"2011","author":"Wojewodka","year":"2011","journal-title":"J Lipids"},{"key":"10.1016\/j.jcf.2015.03.003_bb0170","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm1748","article-title":"Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis","volume":"14","author":"Teichgraber","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0175","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJMoa021218","article-title":"Association of cystic fibrosis with abnormalities in fatty acid metabolism","volume":"350","author":"Freedman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0180","doi-asserted-by":"crossref","first-page":"14677","DOI":"10.1074\/jbc.M300218200","article-title":"Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells autacoids in anti-inflammation","volume":"278","author":"Hong","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2015.03.003_bb0185","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1165\/rcmb.2010-0156OC","article-title":"Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: implication of PKC-potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17kD in asthma","volume":"45","author":"Morin","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0190","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jcf.2015.02.008","article-title":"Host-pathogen interplay in the respiratory environment of cystic fibrosis","volume":"14","author":"Yonker","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2015.03.003_bb0195","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1172\/JCI2357","article-title":"Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells","volume":"102","author":"Kelley","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0200","doi-asserted-by":"crossref","first-page":"L1286","DOI":"10.1152\/ajplung.00127.2003","article-title":"Statin-mediated correction of STAT1 signaling and inducible nitric oxide synthase expression in cystic fibrosis epithelial cells","volume":"285","author":"Kreiselmeier","year":"2003","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0205","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1465-9921-14-138","article-title":"Intrinsic predisposition of naive cystic fibrosis T cells to differentiate towards a Th17 phenotype","volume":"14","author":"Kushwah","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.jcf.2015.03.003_bb0210","doi-asserted-by":"crossref","first-page":"L677","DOI":"10.1152\/ajplung.00030.2009","article-title":"Dysfunctional cystic fibrosis transmembrane conductance regulator inhibits phagocytosis of apoptotic cells with proinflammatory consequences","volume":"297","author":"Vandivier","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0215","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.biocel.2014.03.006","article-title":"Redox balance in cystic fibrosis","volume":"52C","author":"Ziady","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0220","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.4049\/jimmunol.1103661","article-title":"Atypical activation of the unfolded protein response in cystic fibrosis airway cells contributes to p38 MAPK-mediated innate immune responses","volume":"189","author":"Blohmke","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0225","doi-asserted-by":"crossref","first-page":"7764","DOI":"10.4049\/jimmunol.180.11.7764","article-title":"Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease","volume":"180","author":"Blohmke","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0230","doi-asserted-by":"crossref","first-page":"22299","DOI":"10.1074\/jbc.M109.098566","article-title":"Loss of cystic fibrosis transmembrane conductance regulator function enhances activation of p38 and ERK MAPKs, increasing interleukin-6 synthesis in airway epithelial cells exposed to Pseudomonas aeruginosa","volume":"285","author":"Berube","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2015.03.003_bb0235","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1152\/jappl.1993.75.6.2419","article-title":"Systemic deficiency of glutathione in cystic fibrosis","volume":"75","author":"Roum","year":"1993","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0240","doi-asserted-by":"crossref","first-page":"L31","DOI":"10.1152\/ajplung.2001.281.1.L31","article-title":"Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice","volume":"281","author":"Velsor","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0245","doi-asserted-by":"crossref","first-page":"C323","DOI":"10.1152\/ajpcell.1998.275.1.C323","article-title":"Glutathione permeability of CFTR","volume":"275","author":"Linsdell","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0250","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1164\/ajrccm.162.4.9910106","article-title":"Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation","volume":"162","author":"Cantin","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0255","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1189\/jlb.1009655","article-title":"CFTR-mediated halide transport in phagosomes of human neutrophils","volume":"87","author":"Painter","year":"2010","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0260","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1099\/mic.0.2008\/023200-0","article-title":"Burkholderia cenocepacia-induced delay of acidification and phagolysosomal fusion in cystic fibrosis transmembrane conductance regulator (CFTR)-defective macrophages","volume":"154","author":"Lamothe","year":"2008","journal-title":"Microbiology"},{"key":"10.1016\/j.jcf.2015.03.003_bb0265","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.4049\/jimmunol.1201607","article-title":"Reduced caveolin-1 promotes hyperinflammation due to abnormal heme oxygenase-1 localization in lipopolysaccharide-challenged macrophages with dysfunctional cystic fibrosis transmembrane conductance regulator","volume":"190","author":"Zhang","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0270","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1183\/09031936.00228013","article-title":"CFTR: cystic fibrosis and beyond","volume":"44","author":"Mall","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2015.03.003_bb0275","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ni.2921","article-title":"Neutrophils at work","volume":"15","author":"Nauseef","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0280","doi-asserted-by":"crossref","first-page":"C262","DOI":"10.1152\/ajpcell.00070.2005","article-title":"Oxidant stress suppresses CFTR expression","volume":"290","author":"Cantin","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0285","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1164\/rccm.201205-0875OC","article-title":"Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo","volume":"187","author":"Le Gars","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0290","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jcf.2012.07.003","article-title":"Innate immunity in cystic fibrosis lung disease","volume":"11","author":"Hartl","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2015.03.003_bb0295","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1476-5381.2009.00448.x","article-title":"Proteases and antiproteases in chronic neutrophilic lung disease \u2014 relevance to drug discovery","volume":"158","author":"Greene","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0300","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm1690","article-title":"Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease","volume":"13","author":"Hartl","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0305","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1073\/pnas.1200470109","article-title":"NSP4, an elastase-related protease in human neutrophils with arginine specificity","volume":"109","author":"Perera","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2015.03.003_bb0310","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.110.002733","article-title":"Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases","volume":"62","author":"Korkmaz","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jcf.2015.03.003_bb0315","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.4049\/jimmunol.181.7.4945","article-title":"Neutrophil elastase mediates innate host protection against Pseudomonas aeruginosa","volume":"181","author":"Hirche","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0320","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1203\/01.pdr.0000250043.90468.c2","article-title":"Cathepsin-G interferes with clearance of Pseudomonas aeruginosa from mouse lungs","volume":"61","author":"Sedor","year":"2007","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jcf.2015.03.003_bb0325","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1164\/rccm.201311-1932OC","article-title":"Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease","volume":"189","author":"Gehrig","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0330","first-page":"529","article-title":"Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis","volume":"132","author":"Bruce","year":"1985","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2015.03.003_bb0335","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1172\/JCI114492","article-title":"Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells","volume":"85","author":"Sommerhoff","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0340","first-page":"L835","article-title":"Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells","volume":"276","author":"Voynow","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0345","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1172\/JCI114298","article-title":"Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis","volume":"84","author":"Berger","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0350","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1172\/JCI114699","article-title":"Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch","volume":"86","author":"Tosi","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0355","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1172\/JCI0213572","article-title":"Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis","volume":"109","author":"Vandivier","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0360","doi-asserted-by":"crossref","first-page":"89S","DOI":"10.1378\/chest.121.3_suppl.89S","article-title":"Impaired clearance of apoptotic cells from cystic fibrosis airways","volume":"121","author":"Vandivier","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0365","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.4049\/jimmunol.1300711","article-title":"Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung","volume":"192","author":"Vega-Carrascal","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0370","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1183\/09031936.00173210","article-title":"The role of matrix metalloproteinases in cystic fibrosis lung disease","volume":"38","author":"Gaggar","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2015.03.003_bb0375","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1165\/rcmb.2013-0407OC","article-title":"Airway mucus obstruction triggers macrophage activation and matrix metalloproteinase 12-dependent emphysema","volume":"51","author":"Trojanek","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0380","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ppul.20165","article-title":"Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis","volume":"39","author":"Sagel","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0385","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1074\/jbc.M110.183863","article-title":"Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme\/meprin\/epidermal growth factor receptor\/toll-like receptor pathway","volume":"286","author":"Cosgrove","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2015.03.003_bb0390","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.4049\/jimmunol.180.8.5662","article-title":"A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation","volume":"180","author":"Gaggar","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0395","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1164\/rccm.201311-1986OC","article-title":"miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production","volume":"190","author":"Weldon","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0400","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1183\/09031936.00146807","article-title":"Inhibition of airway proteases in cystic fibrosis lung disease","volume":"32","author":"Griese","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2015.03.003_bb0405","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.rmed.2007.11.011","article-title":"Different expression ratio of S100A8\/A9 and S100A12 in acute and chronic lung diseases","volume":"102","author":"Lorenz","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0410","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/imm.12352","article-title":"S100A8, S100A9 and S100A12 activate airway epithelial cells to produce MUC5AC via extracellular signal-regulated kinase and nuclear factor-kappaB pathways","volume":"144","author":"Kang","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.jcf.2015.03.003_bb0415","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jaci.2005.09.023","article-title":"Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis","volume":"117","author":"Hartl","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0420","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1164\/rccm.201207-1346OC","article-title":"Th17\/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines","volume":"187","author":"Iannitti","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0425","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1365-2249.2000.01232.x","article-title":"Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes","volume":"120","author":"Moss","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0430","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.4049\/jimmunol.1202144","article-title":"Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease","volume":"190","author":"Rieber","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0435","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3109\/08820139.2014.888447","article-title":"CD4(+)CD25(high) FOXP3(+) regulatory T cells correlate with FEV1 in North Indian children with cystic fibrosis","volume":"43","author":"Anil","year":"2014","journal-title":"Immunol Invest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0440","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12016-007-8039-9","article-title":"Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling","volume":"34","author":"Nichols","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0445","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0450","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1164\/rccm.200307-959OC","article-title":"Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis","volume":"169","author":"Paul","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0455","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1378\/chest.12-0628","article-title":"Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa","volume":"142","author":"Ratjen","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0460","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199503303321303","article-title":"Effect of high-dose ibuprofen in patients with cystic fibrosis","volume":"332","author":"Konstan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0465","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ppul.21388","article-title":"Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis","volume":"46","author":"Konstan","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0470","first-page":"354","article-title":"High dose ibuprofen significantly improves long-term CF survival","volume":"47","author":"VanDevanter","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0475","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0480","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0140-6736(85)92929-0","article-title":"Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis","volume":"2","author":"Auerbach","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2015.03.003_bb0485","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0022-3476(95)70343-8","article-title":"A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis Cystic Fibrosis Foundation Prednisone Trial Group","volume":"126","author":"Eigen","year":"1995","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2015.03.003_bb0490","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJM200003233421204","article-title":"Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis","volume":"342","author":"Lai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0495","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jpeds.2008.07.010","article-title":"Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis","volume":"153","author":"Ren","year":"2008","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2015.03.003_bb0500","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00148581-200911020-00002","article-title":"The role of inhaled corticosteroids in the management of cystic fibrosis","volume":"11","author":"Ross","year":"2009","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jcf.2015.03.003_bb0505","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1164\/rccm.200511-1808OC","article-title":"Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis","volume":"173","author":"Balfour-Lynn","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0510","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpeds.2007.04.009","article-title":"High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial","volume":"151","author":"Lands","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2015.03.003_bb0515","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.200702-181OC","article-title":"Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis","volume":"176","author":"Konstan","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0520","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MCP.0b013e32831311e8","article-title":"Ibuprofen therapy for cystic fibrosis lung disease: revisited","volume":"14","author":"Konstan","year":"2008","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0525","first-page":"CD001505","article-title":"Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis","volume":"6","author":"Lands","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2015.03.003_bb0530","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1164\/rccm.200306-731OC","article-title":"Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis","volume":"168","author":"Ordonez","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0535","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199306173282403","article-title":"Efficacy of aerosolized tobramycin in patients with cystic fibrosis","volume":"328","author":"Ramsey","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0540","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ppul.21176","article-title":"Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas","volume":"45","author":"Noah","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0545","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2015.03.003_bb0550","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ppul.21601","article-title":"Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa","volume":"47","author":"Saiman","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0555","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ppul.22890","article-title":"Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection","volume":"49","author":"Milla","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0560","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1164\/ajrccm.165.8.2107051","article-title":"Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice","volume":"165","author":"Chmiel","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0565","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1164\/ajrccm.160.6.9901043","article-title":"IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice","volume":"160","author":"Chmiel","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0570","doi-asserted-by":"crossref","first-page":"L303","DOI":"10.1152\/ajplung.90276.2008","article-title":"Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium","volume":"295","author":"Perez","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0575","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/jcp.20020","article-title":"Decreased expression of peroxisome proliferator activated receptor gamma in cftr-\/-mice","volume":"200","author":"Ollero","year":"2004","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0580","first-page":"289","article-title":"A pilot study evaluating the effect of pioglitazone, simvastatin, and ibuprofen on neutrophil migration in vivo in healthy subjects","volume":"42","author":"Konstan","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0585","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1172\/JCI9560","article-title":"In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium","volume":"106","author":"Kelley","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0590","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/(SICI)1096-9896(199803)184:3<323::AID-PATH2>3.0.CO;2-2","article-title":"Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis","volume":"184","author":"Meng","year":"1998","journal-title":"J Pathol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0595","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1165\/ajrcmb.22.1.3789","article-title":"Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression","volume":"22","author":"Steagall","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0600","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ppul.20152","article-title":"Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease","volume":"39","author":"Moss","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0605","doi-asserted-by":"crossref","first-page":"L604","DOI":"10.1152\/ajplung.00459.2001","article-title":"Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells","volume":"283","author":"Kraynack","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0610","first-page":"S300","article-title":"Effect of simvastatin on exhaled nitric oxide and inflammatory markers in sputum in patients with cystic fibrosis","volume":"43","author":"Kraynack","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0615","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1164\/rccm.200502-253OC","article-title":"Increased arginase activity in cystic fibrosis airways","volume":"172","author":"Grasemann","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0620","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1183\/09031936.04.00086104","article-title":"Oral l-arginine supplementation in cystic fibrosis patients: a placebo-controlled study","volume":"25","author":"Grasemann","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2015.03.003_bb0625","doi-asserted-by":"crossref","first-page":"e3367","DOI":"10.1371\/journal.pone.0003367","article-title":"Dysfunction of Nrf-2 in CF epithelia leads to excess intracellular H2O2 and inflammatory cytokine production","volume":"3","author":"Chen","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2015.03.003_bb0630","doi-asserted-by":"crossref","first-page":"L828","DOI":"10.1152\/ajplung.00171.2009","article-title":"The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease","volume":"297","author":"Nichols","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0635","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jcf.2012.08.016","article-title":"Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis","volume":"12","author":"Moss","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2015.03.003_bb0640","doi-asserted-by":"crossref","first-page":"404","DOI":"10.4049\/jimmunol.175.1.404","article-title":"Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis","volume":"175","author":"McAllister","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0645","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/ajrccm\/148.4_Pt_1.896","article-title":"Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis","volume":"148","author":"Konstan","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2015.03.003_bb0650","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jcf.2013.12.009","article-title":"A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis","volume":"13","author":"Konstan","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2015.03.003_bb0655","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcf.2013.10.007","article-title":"BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs","volume":"13","author":"Doring","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2015.03.003_bb0660","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1183\/09031936.00047306","article-title":"alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients","volume":"29","author":"Griese","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2015.03.003_bb0665","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/01.mcp.0000138997.29276.a1","article-title":"Potential for antioxidant therapy of cystic fibrosis","volume":"10","author":"Cantin","year":"2004","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0670","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1051\/medsci\/20072319","article-title":"Oxidative stress, smoking and CFTR: can cystic fibrosis be acquired?","volume":"23","author":"Ouellet","year":"2007","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.jcf.2015.03.003_bb0675","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1152\/jappl.1993.75.6.2419","article-title":"1993. Systemic deficiency of glutathione in cystic fibrosis","volume":"75","author":"Roum","year":"1985","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0680","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1378\/chest.127.1.308","article-title":"A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis","volume":"127","author":"Bishop","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2015.03.003_bb0685","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.freeradbiomed.2005.03.032","article-title":"Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs","volume":"39","author":"Hartl","year":"2005","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0690","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/rccm.201303-0427OC","article-title":"Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial","volume":"188","author":"Griese","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0695","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1073\/pnas.0511304103","article-title":"High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis","volume":"103","author":"Tirouvanziam","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2015.03.003_bb0700","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcf.2014.08.008","article-title":"Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial","volume":"14","author":"Conrad","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2015.03.003_bb0705","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1203\/PDR.0b013e3181b4e8d3","article-title":"Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy","volume":"66","author":"Aldamiz-Echevarria","year":"2009","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jcf.2015.03.003_bb0710","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.plefa.2007.12.005","article-title":"Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients","volume":"78","author":"Van Biervliet","year":"2008","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.jcf.2015.03.003_bb0715","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ni1056","article-title":"Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway","volume":"5","author":"Karp","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0720","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/gt.2008.156","article-title":"The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a CFTR-\/--dependent allergy mouse model","volume":"16","author":"Mueller","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.jcf.2015.03.003_bb0725","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1165\/rcmb.2006-0323OC","article-title":"Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice","volume":"36","author":"Saadane","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2015.03.003_bb0730","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/thx.2007.089359","article-title":"Characterisation of the range of neutrophil stimulating mediators in cystic fibrosis sputum","volume":"63","author":"Mackerness","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2015.03.003_bb0735","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.freeradbiomed.2006.09.022","article-title":"Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11\u201312, 2003","volume":"42","author":"Cantin","year":"2007","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jcf.2015.03.003_bb0740","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1023\/A:1016076907072","article-title":"Degradation kinetics of DMP 777, an elastase inhibitor","volume":"13","author":"Raghavan","year":"1996","journal-title":"Pharm Res"},{"key":"10.1016\/j.jcf.2015.03.003_bb0745","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/jpet.106.103440","article-title":"EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis","volume":"318","author":"Attucci","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jcf.2015.03.003_bb0750","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1183\/09031936.00073710","article-title":"SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition","volume":"37","author":"Cooley","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2015.03.003_bb0755","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1172\/JCI115994","article-title":"Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor","volume":"90","author":"McElvaney","year":"1992","journal-title":"J Clin Invest"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199315000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199315000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T16:56:51Z","timestamp":1598893011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199315000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":151,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1569199315000582"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2015.03.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2015.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}